Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triptorelin - Debiopharm

Drug Profile

Triptorelin - Debiopharm

Alternative Names: ARVEKAP; AY 25650; BIM 21003; BN 52014; CL 118532; Debio 8200; Debio 8206; Debio 8206 CPP; Debio 8206 SC; debio8200; Decapeptyl; Decapeptyl SR; Diphereline; Moapar; Pamorelin; Pamorelin LA; Salvacyl; Trelstar; Trelstar Depot; Triptodur; Triptorelin acetate; Triptorelin embonate; Triptorelin pamoate; Triptoreline; Tryptorelin; WY 42422

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tulane University
  • Developer Allergan; Arbor Pharmaceuticals; Debiopharm; European Organisation for Research and Treatment of Cancer; Ipsen; Orient Europharma; Pfizer; United Laboratories
  • Class Antineoplastics; Antivirals; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precocious puberty
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Female infertility; Paraphilias; Precocious puberty; Prostate cancer; Uterine leiomyoma
  • Phase II Salivary gland cancer
  • Phase I Malignant melanoma

Most Recent Events

  • 17 Sep 2018 Phase-III clinical trials in Prostate cancer in China (IM, Controlled release, Six-month) (Ipsen pipeline, September 2018)
  • 15 Jun 2018 Phase-III clinical trials in Precocious puberty in China (IM) (Ipsen pipeline, June 2018)
  • 08 May 2018 Phase-I clinical trials in Malignant melanoma (Combination therapy, Late-stage disease) (unspecified) (Debiopharm pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top